cobimetinib
Selected indexed studies
- Cobimetinib. (, 2006) [PMID:29999907]
- Cobimetinib. (Ann Pharmacother, 2017) [PMID:27701080]
- Cobimetinib. (, 2012) [PMID:31643968]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. (2022) pubmed
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. (2019) pubmed
- Cobimetinib. (2006) pubmed
- Cobimetinib. (2017) pubmed
- Cobimetinib. (2012) pubmed
- Cobimetinib (GDC-0973, XL518). (2018) pubmed
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- PMID:29144709 (2016) pubmed
- Cobimetinib for metastatic melanoma. (2017) pubmed
- Cobimetinib: First Global Approval. (2015) pubmed